Charles Glaus is a Senior Director in the Research and Early Development Oncology organization at Bayer Pharmaceuticals and is responsible for directing imaging and radiomics approaches across the global oncology portfolio. In this role Charles leads development of advanced imaging biomarkers, including artificial intelligence-based approaches, and implements these methods into clinical development programs to help accelerate throughput of Bayer’s early oncology pipeline.

Charles joined Bayer from Takeda Pharmaceuticals where he led imaging activities across the oncology portfolio, including imaging-derived endpoints for global clinical trials, radiomics, translational imaging, and internal and external research collaborations. Prior to joining Takeda Charles was head of the Research Imaging Sciences group at Amgen, a multimodal imaging laboratory utilizing advanced technology to support translational imaging in oncology, cardiometabolic disorders, inflammation, and neuroscience therapeutic areas.

He earned a B.S. in Physics from the University of Missouri where he conducted research in computational physics and neutron irradiation of magnetic materials. He earned a PhD in Biomedical Engineering from the Georgia Institute of Technology and Emory University School of Medicine in the laboratory of Gang Bao where he developed nanotechnology-based probes for molecular imaging applications in cancer and cardiovascular disease. Charles then joined the Radiology department at Washington University School of Medicine as a postdoctoral research associate in the laboratory of Michael J. Welch, Head of Oncologic Imaging Research at the Siteman Cancer Center, where he designed probes and methods for PET imaging of cancer and helped establish GMP production of immuno-PET radiopharmaceuticals for clinical studies.